Navigation Links
The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies

BOSTON, Dec. 7 /PRNewswire/ -- The Epilepsy Research Foundation (ERF), a unique joint venture of non-profit epilepsy organizations, and the Milken Family Foundation, a private philanthropic foundation, today announced two new grants recognizing promising epilepsy research in clinical development, totaling $225,000 in funding. The grant awards were announced by the Epilepsy Therapy Project and the Epilepsy Foundation, as well as the Milken Family Foundation, during the 7th Judith Hoyer Lecture in Epilepsy at the annual meeting of the American Epilepsy Society in Boston, MA.

These grants are designated to support critical stages of advancement - through early clinical or to bridge from preclinical to clinical development - for groundbreaking therapies in epilepsy. The award committee, comprised of clinical, scientific and industry representatives, evaluates research programs demonstrating the greatest potential for near-term patient benefit and pioneered by qualified clinicians and scientists advancing new therapeutic approaches in epilepsy and the central nervous system. The two recipients announced today have been recognized for promising clinical work in advancing a novel agent, 2-deoxy-D-glucose (2DG), for control and reduction of seizure frequency, and a new therapeutic specifically designed for the treatment of newborns with hypoxic brain injuries resulting in seizure-related conditions.

"These awards recognize important advances in the treatment of epilepsy, providing new hope for patients living with uncontrolled seizures and for newborns with serious brain cell injury," said Warren Lammert, Chairman, Epilepsy Therapy Project. "Funding today for new therapies is limited, and with these awards we are able to advance important research through critical junctures so that innovators can broadly access resources necessary to bring these new treatments to patients."

"Epilepsy affects nearly three million people in the United States and 50 million people worldwide," said Eric R. Hargis, President and CEO of the Epilepsy Foundation. "Even with current treatments, approximately 30 percent of people with epilepsy live with uncontrolled seizures. Our goal in awarding these grants is to help provide them with new and better treatment options."

"We are gravely in need of novel epilepsy treatments with new underlying modes of action for all patients living with seizure conditions, and in particular to provide more effective options for young children and for women of childbearing age," said Howard R. Soule, Ph.D., Chief Science Officer for the Milken Family Foundation. "We are proud to support high-caliber research in the field of epilepsy, and truly hope to see progress in making available effective and tolerable treatments in our lifetimes."

The December 2009 Grant Recipients

Benefits of the Ketogenic Diet Lead to Discovery of New Anticonvulsant

Nathan Fountain, M.D., Director, F.E. Dreifuss Comprehensive Epilepsy Program, University of Virginia and Thomas Sutula, M.D., Ph.D., Detling Professor and Chair, University of Wisconsin-Madison and Co-founder, Chief Technical Officer of NeuroGenomeX, Inc., will be assessing the clinical activity of 2-deoxy-D-glucose (2DG) in reducing seizure frequency in subjects with a history of frequent seizures. The investigators will use the grant funding in an initial Phase II safety, tolerability and proof-of-principle clinical study of 2DG. By investigating the mechanisms of anticonvulsant action of the ketogenic diet (isocaloric replacement of carbohydrates by fats and proteins), researchers identified the inhibition of glycolysis as a novel mechanism of anticonvulsant and antiepileptic action. Administration of 2DG, a known inhibitor of glycolysis, also demonstrated acute anticonvulsant action in early evaluation, and had pronounced anticonvulsant and antiepileptic effects in preclinical studies. Importantly, the pattern of anticonvulsant efficacy of 2DG in screening models is distinctive as compared to currently available drugs. 2DG has a well-established preclinical efficacy and toxicity profile, with decades of use as an imaging tracer, as well as safety established during previous Phase I/II human clinical trials for cancer.

Demonstration of efficacy in this initial clinical proof-of-principle trial would be a substantial milestone in the development of 2DG as a therapy for seizure disorders by adding evidence of efficacy and safety to current preclinical evidence in epilepsy animal models.

New Therapeutic with Promise for Neuroprotection and Treatment in Neonatal Care

A University of Minnesota research team headed by James Cloyd, PharmD, Professor of Experimental & Clinical Pharmacology, Lawrence C. Weaver Endowed Chair-Orphan Drug Development, and Director, Center for Orphan Drug Research, received funding to support the study of an intravenous formulation of the anticonvulsant Topiramate (TPM), a drug that has demonstrated important neuroprotective properties in preclinical models. Topiramate, in its oral formulation, is currently prescribed to treat epilepsy in children and adults. In this program, researchers are pursuing the long-term goal of developing a novel, FDA-approved, intravenous topiramate for the neuroprotection and treatment of seizures in neonates with hypoxic brain injuries. An estimated 15,000 neonates experience seizures, which cause brain injury and death. Current therapy is only partially effective and is associated with serious adverse effects. The National Institutes of Neurological Disorders and Stroke has identified improved treatment of neonatal seizures as a significant unmet need.

Grant funding will be applied to conduct a safety and pharmacokinetics study of a new IV and oral topiramate in healthy volunteers.

About Epilepsy

When a person has two or more unprovoked seizures, they have epilepsy, which affects nearly 3 million people in the United States and 40 to 50 million people worldwide. This year, another 200,000 people in our country will be diagnosed with epilepsy. To date, there is no known cure.

About the Epilepsy Research Foundation

The Epilepsy Research Foundation was created to support the development of new, innovative translational research in producing new therapies and a cure for epilepsy. The organization was formed by the Epilepsy Therapy Project and the Epilepsy Foundation and includes support from Finding A Cure for Epilepsy and Seizures (FACES). All money raised goes directly toward highly promising research projects that can be fast tracked in the fight against seizures. For further information, or to contribute, please visit or

About the Epilepsy Foundation

The Epilepsy Foundation, a national non-profit with affiliated organizations throughout the United States, has led the fight against epilepsy since 1968. The Foundation's goals are to ensure that people with seizures are able to participate in all life experiences; and to prevent, control and cure epilepsy through services, education, advocacy and research, so not another moment is lost to seizures. For additional information, please visit

Milken Family Foundation

Epilepsy Research Awards Program

The Milken Family Foundation Epilepsy Research Awards Program includes two programs that foster an entrepreneurial approach to research that is conducive to new ideas, the determination to move promising treatments to trial, and the commitment to share advances and findings. The Early Career Physician-Scientist Awards Program, in partnership with the American Epilepsy Society, presents research awards of $50,000 each to active scientists and clinicians embarking on careers in academic medicine and seeking to develop outstanding epilepsy research programs. The Milken Translational Research Awards Program, in partnership with the Epilepsy Therapy Project, grants $50,000 each to physicians and scientists with demonstrated skills in advancing new treatments for patients.

About the Milken Family Foundation

Established by Lowell and Michael Milken in 1982, the mission of the Milken Family Foundation (MFF) is to discover and advance effective ways of helping people help themselves and those around them lead productive and satisfying lives. MFF pursues this mission primarily through signature initiatives in education and medical research. More information is at

About the Epilepsy Therapy Project

The Epilepsy Therapy Project is a 501(c) (3) non-profit organization whose mission is to accelerate ideas into therapies for people living with epilepsy and seizures. Founded in 2002 by a group of parents, distinguished physicians, and researchers, the Epilepsy Therapy Project supports the commercialization of new therapies through direct grants and investments in promising academic and commercial projects. For more information about epilepsy, epilepsy treatment and the epilepsy pipeline, please visit or call 540-687-8077.

SOURCE Epilepsy Therapy Project

SOURCE Epilepsy Therapy Project
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment
2. Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
3. VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful
4. Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy
5. New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy
6. Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. New Research Shows a Vitamin/Nutriceutical Formulation Improves Memory and Cognitive Performance in Community-Dwelling Adults
9. Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker
10. Alzheimers Research May Lead to Preventing the Debilitating Disease
11. Reportlinker Adds Contract Research Outsourcing (CRO) - A Global Update of Market Trends & Opportunities
Post Your Comments:
(Date:10/13/2015)... MENLO PARK, Calif. , Oct. 13, 2015 ... contract of up to $100 million over five ... Infectious Diseases (NIAID), part of the National Institutes ... mitigate or treat acute or delayed effects of ... Biosciences , a division of SRI International will ...
(Date:10/13/2015)...  Nanomedical Diagnostics, a biotech company developing and ... announces the completion of a Series A financing ... --> --> ... and diagnostic platforms that empower individuals to make ... enable the company to commercially release AGILE Research, ...
(Date:10/13/2015)... Oct. 13 2015 ... "US & European markets for Meniscal Repair ... offering. --> ) has announced ... markets for Meniscal Repair - 16 Countries (2010-2021)" ... Research and Markets ( ) has announced ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 13, 2015 , ... Symposium Chairman, Dr. Rod J. Rohrich is pleased to ... be held March 2nd and 3rd, 2016. The annual meeting, along with the ... physicians from around the world. , Key topics at this year's event will include ...
(Date:10/13/2015)... ... 13, 2015 , ... Relay (, a technology company that ... significant contract that will provide its award-winning private messaging solution to Independence Blue ... success of its Relay program, IBX Wire™, which now has over 550,000 members ...
(Date:10/13/2015)... ... 13, 2015 , ... NavaFit Inc. today announced the launch of its NavaFit ... participate in local fitness & sporting events, and stay motivated. Users can ... costs drive us to get more serious about fitness and wellness, individuals are constantly ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Protein is ... the body, including muscle, bone, and blood. But how much protein does the average ... than it might seem, according to the October 2015 issue of Harvard Men's ...
(Date:10/13/2015)... ... 2015 , ... Scientists in Seattle and Vancouver compared the diagnostic value of ... mesothelioma. Surviving Mesothelioma has just posted an article on the new research. Click ... and the University of British Columbia found that certain genetic alterations were seen just ...
Breaking Medicine News(10 mins):